NASDAQ:DRUG

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

$1.10
+0.01 (+0.92%)
(As of 04/26/2024 ET)
Today's Range
$1.05
$1.13
50-Day Range
$1.09
$1.95
52-Week Range
$1.05
$6.44
Volume
6,530 shs
Average Volume
17,470 shs
Market Capitalization
$4.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DRUG stock logo

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

DRUG Stock Price History

DRUG Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Bright Minds Biosciences Inc. (DRUG.CN)
DRUG Bright Minds Biosciences Inc.
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Bright Minds Announces Proposed Share Consolidation
See More Headlines
Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
4/27/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRUG
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-5,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.30 per share

Miscellaneous

Free Float
2,542,000
Market Cap
$4.87 million
Optionable
Not Optionable
Beta
1.41
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Ian McDonald (Age 35)
    Co-Founder, CEO, President & Director
  • Mr. Ryan E. S. K. Cheung B.Com. (Age 46)
    CA, CPA, Chief Financial Officer
    Comp: $88.2k
  • Dr. Jan Torleif Pedersen M.Sc. (Age 59)
    Ph.D., Chief Science Officer & Director
    Comp: $179.01k
  • Dr. Mark A. Smith M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $240.74k
  • Dr. Emer Leahy M.B.A. (Age 57)
    Ph.D., Consultant

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed in 2024?

Bright Minds Biosciences' stock was trading at $1.43 at the beginning of the year. Since then, DRUG stock has decreased by 23.1% and is now trading at $1.10.
View the best growth stocks for 2024 here
.

Are investors shorting Bright Minds Biosciences?

Bright Minds Biosciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 75,700 shares, an increase of 7.2% from the March 31st total of 70,600 shares. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.8% of the shares of the company are short sold.
View Bright Minds Biosciences' Short Interest
.

When is Bright Minds Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our DRUG earnings forecast
.

How were Bright Minds Biosciences' earnings last quarter?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.32) EPS for the quarter.

When did Bright Minds Biosciences' stock split?

Shares of Bright Minds Biosciences reverse split on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRUG) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners